Recent developments in weight-loss treatments have impacted the market significantly. Viking Therapeutics' new pill showed ...

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

Wall Street held near its record heights Monday, ahead of a week likely to be dominated by updates from the head of the ...

Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from the head of the ...

BANGKOK — World shares were mixed on Tuesday after Wall Street held near its records, with traders awaiting fresh cues about ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.